HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.

Abstract
Gemcitabine is widely used for pancreatic, lung, and bladder cancer. However, drug resistance against gemcitabine is a large obstacle to effective chemotherapy. Nucleoside transporters, nucleoside and nucleotide metabolic enzymes, and efflux transporters have been reported to be involved in gemcitabine resistance. Although most of the resistant factors are supposed to be related to each other, it is unclear how one factor can affect the other one. In this study, we established gemcitabine-resistant pancreatic cancer cell lines. Gemcitabine resistance in these cells is caused by two major processes: a decrease in gemcitabine uptake and overexpression of ribonucleotide reductase large subunit (RRM1). Knockdown of RRM1, but not the overexpression of concentrative nucleoside transporter 1 (CNT1), could completely overcome the gemcitabine resistance. RRM1 knockdown in gemcitabine-resistant cells could increase the intracellular accumulation of gemcitabine by increasing the nucleoside transporter expression. Furthermore, a synergistic effect was observed between hydroxyurea, a ribonucleotide reductase (RR) inhibitor, and gemcitabine on the gemcitabine-resistant cells. Here we indicate that RR is one of the most promising targets to overcome gemcitabine resistance in gemcitabine-resistant cells with dual resistant factors.
AuthorsKentaro Minami, Yoshinari Shinsato, Masatatsu Yamamoto, Homare Takahashi, Shaoxuan Zhang, Yukihiko Nishizawa, Sho Tabata, Ryuji Ikeda, Kohich Kawahara, Kazutake Tsujikawa, Kazuo Chijiiwa, Katsushi Yamada, Shin-ichi Akiyama, Sandra Pérez-Torras, Marcal Pastor-Anglada, Tatsuhiko Furukawa, Takeda Yasuo
JournalJournal of pharmacological sciences (J Pharmacol Sci) Vol. 127 Issue 3 Pg. 319-25 (Mar 2015) ISSN: 1347-8648 [Electronic] Japan
PMID25837929 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. All rights reserved.
Chemical References
  • Antimetabolites, Antineoplastic
  • Enzyme Inhibitors
  • Deoxycytidine
  • Ribonucleotide Reductases
  • Gemcitabine
Topics
  • Antimetabolites, Antineoplastic (pharmacology)
  • Deoxycytidine (analogs & derivatives, metabolism, pharmacology)
  • Drug Resistance, Neoplasm (genetics)
  • Enzyme Inhibitors (metabolism, pharmacology)
  • Humans
  • Pancreatic Neoplasms (metabolism, pathology)
  • Ribonucleotide Reductases (antagonists & inhibitors, physiology)
  • Tumor Cells, Cultured
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: